Anti Amyloid Kisunla denied as not medically necessary by Humana?

Humana's specific coverage criteria for anti amyloid kisunla are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Kisunla on Medical-Necessity Grounds

Kisunla (donanemab) is an FDA-approved anti-amyloid monoclonal antibody indicated for early symptomatic Alzheimer's disease. Humana's medical-necessity denials for this drug are driven by the plan's coverage policy, which sets specific diagnostic, cognitive staging, and eligibility criteria that must be documented before the plan will authorize coverage. Common reasons for denial include insufficient cognitive staging documentation, the absence of amyloid confirmation results in the submission, or failure to document that the patient's presentation falls within the approved population.

## Why This Denial Is Appealable

Alzheimer's disease is a progressive condition and delay in treatment is not clinically neutral. If the patient's chart genuinely reflects the criteria in Humana's coverage policy and the FDA prescribing label, a medical-necessity denial is a documentation problem, not a clinical one. When the appeal presents a complete, well-organized record, these denials are frequently overturned — particularly at the external review stage, where reviewers assess clinical standards independently of the plan's administrative posture.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): Submit a written appeal with complete clinical documentation. Non-urgent: Humana must respond within 60 days. Urgent: 72 hours.
• External review: If the internal appeal is denied, independent external review is available under ACA §2719. File within approximately four months of the final internal denial. An independent clinical reviewer determines whether the denial was consistent with medical evidence.
• Expedited review: Given the progressive nature of Alzheimer's, request expedited processing if clinical deterioration is occurring or is likely during the standard review period.

## Documentation to Gather

1. Confirmed Alzheimer's diagnosis — neurologist or dementia specialist notes, cognitive testing results, and documentation of clinical presentation consistent with early symptomatic disease. 2. Amyloid confirmation — results from amyloid PET imaging or CSF biomarker testing confirming amyloid pathology, as required per the FDA-approved indication in the prescribing label. 3. Cognitive staging documentation — validated cognitive assessment scores recorded in the chart; functional assessment reflecting the staging consistent with the label's approved population. (Do not cite specific score cutoffs here — confirm with the label and Humana's policy for the exact thresholds required.) 4. Prescriber medical-necessity letter — from the treating neurologist or dementia specialist explicitly mapping the patient's clinical status to each requirement in Humana's published coverage policy and the FDA prescribing label. 5. Humana's coverage policy — obtain the exact current policy document cited in the denial letter. List each criterion and map it to a specific chart entry or test result in your appeal. 6. Absence of safety exclusions — document that the prescriber has reviewed the FDA label's safety considerations and that the patient's clinical profile is appropriate for treatment per the prescriber's judgment.

## Criteria-Mapping Structure

Structure your appeal letter as a numbered checklist that mirrors Humana's coverage criteria in order. For each criterion: quote the language from the policy, identify the corresponding chart document or test result, and cite the specific date. Attach all referenced documents as numbered exhibits. This format makes the reviewer's approval pathway explicit and leaves no criterion unaddressed.